Cat. No. | Product name | CAS No. |
DC7436 |
JAK2 Inhibitor V,Z3
Featured
Z3(NSC 42834), a novel specific inhibitor of Jak2, inhibits Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity. |
195371-52-9 |
DC7667 |
ZM 39923 hydrochloride
Featured
ZM 39923 is an inhibitor of JAK3 (IC50 = 79 nM) that less potently inhibits epidermal growth factor receptor, JAK1, and cyclin-dependent kinase 4 (IC50s = 2.4, 40, and 10 µM, respectively). |
1021868-92-7 |
DC5199 |
S-Ruxolitinib (INCB018424)
Featured
S-Ruxolitinib is the chirality of INCB018424, which is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3. Phase 3. |
941685-37-6 |
DC40051 |
Fedratinib hydrochloride hydrate
Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research. |
1374744-69-0 |
DC40139 |
JAK-IN-5 hydrochloride
JAK-IN-5 hydrochloride is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283. |
|
DC40168 |
SHR0302
SHR0302 is a potent and orally active all members of the JAK family inhibitor, particularly JAK1. The selectivity of SHR0302 for JAK1 is >10-fold for JAK2, 77-fold for JAK3, 420-fold for Tyk2. SHR0302 inhibits JAK1-STAT3 phosphorylation and induces the apoptosis of hepatic stellate cells. SHR0302 has anti-proliferative and anti-inflammatory effects. |
1445987-21-2 |
DC40459 |
FM-479
Featured
FM-479 is the negative control of FM-381 and has no activity on JAK3 or other kinases. |
2226521-64-6 |
DC40513 |
BD750
Featured
BD750, an effective immunosuppressant and a JAK3/STAT5 inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation, with IC50 values of 1.5 μM and 1.1 μM in mouse and human T cells, respectively. |
892686-59-8 |
DC40757 |
ZM 449829
ZM 449829 is a potent, selective and ATP competitive inhibitor of JAK3, with a pIC50 of 6.8. ZM 449829 will be useful pharmacological tools for the investigation of the JAK3. |
4452-06-6 |
DC41052 |
JAK2-IN-6
JAK2-IN-6, a multiple-substituted aminothiazole derivative, is a potent and selective JAK2 inhibitor with an IC50 of 22.86 μg/mL. JAK2-IN-6 shows no activity against JAK1 and JAK3. JAK2-IN-6 has anti-proliferative effect against cancer cells. |
353512-04-6 |
DC41406 |
Coumermycin A1
Coumermycin A1 is a JAK2 signal activator. Coumermycin A1 inhibits DNA Gyrase which thereby inhibits cell division in bacteria. |
4434-05-3 |
DC42324 |
JAK2-IN-7
JAK2-IN-7 is a selective JAK2 with IC50s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3V617F cells. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities. |
|
DC42325 |
(3S,4S)-Tofacitinib
(3S,4S)-Tofacitinib is the less active S-enantiomer of Tofacitinib. Tofacitinib inhibits JAK3 with IC50 of 1 nM. |
1092578-47-6 |
DC44160 |
JAK2/FLT3-IN-1
JAK2/FLT3-IN-1 is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 has anti-cancer activity. |
2387765-27-5 |
DC46855 |
Deuruxolitinib
Deuruxolitinib (CTP-543), a deuterated Ruxolitinib, modulates the activity of JAK1/JAK2. Deuruxolitinib can be used for the research hair loss disorders (from patent WO2017192905A1, compound I). |
1513883-39-0 |
DC46856 |
JAK2/FLT3-IN-1 TFA
JAK2/FLT3-IN-1 (TFA) is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 (TFA) has anti-cancer activity. |
|
DC46857 |
Nezulcitinib
Nezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (JAK) inhibitor. Nezulcitinib can be used for the research of COVID-19 associated acute lung injury and impaired oxygenation. |
2412496-23-0 |
DC47030 |
Ilunocitinib
Ilunocitinib (compound 27) is a JAK inhibitor (extracted from patent WO2009114512A1). |
1187594-14-4 |
DC47038 |
Fosifidancitinib
Featured
Fosifidancitinib is a potent and selective inhibitor of JAK kinases 1/3. Fociatinib is used in studies of allergies, asthma and autoimmune diseases. |
1237168-58-9 |
DC47039 |
Itacnosertib
Itacnosertib (TP-0184) is both inhibitor to JAK2, ACVR1 (ALK2) and ALK5 as described in WO2014151871. |
1628870-27-8 |
DC47041 |
Lorpucitinib
Lorpucitinib is a Gut-Restricted JAK Inhibitor for the research of Inflammatory Bowel Disease. |
2230282-02-5 |
DC47066 |
Ifidancitinib
Ifidancitinib is a potent and selective inhibitor of JAK kinases 1/3. Ifidancitinib can be used in studies of allergies, asthma and autoimmune diseases. |
1236667-40-5 |